Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,273 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metastatic Prostate Cancer Clear all
Recruiting Phase 2 Interventional

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

NCT04363164
View directory record Official record
Conditions
Castration Resistant Metastatic Prostate Cancer
Interventions
Testosterone cypionate, Enzalutamide, Testosterone enanthate
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
6
States / cities
San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 25, 2026, 5:22 AM EDT
Recruiting Early Phase 1 Interventional

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients

NCT05045066
View directory record Official record
Conditions
Localized Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Locally Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Interventions
Cholecalciferol, Quality-of-Life Assessment, Biospecimen Collection
Dietary Supplement · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
2
States / cities
Scottsdale, Arizona • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

NCT01517802
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer
Interventions
Abiraterone acetate, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
10
States / cities
Aurora, Colorado • Marrero, Louisiana • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 25, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

NCT03849469
View directory record Official record
Conditions
Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions
XmAb®22841, Pembrolizumab (Keytruda®)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 25, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

BKM120 in Metastatic Castration-resistant Prostate Cancer

NCT01385293
View directory record Official record
Conditions
Prostate Cancer, Metastatic (Spread to Other Areas of the Body)
Interventions
BKM120
Drug
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Durham, North Carolina • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 25, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

NCT01106352
View directory record Official record
Conditions
Bone Metastases, Castration-Resistant Prostate Cancer
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
San Francisco, California • Evanston, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 25, 2026, 5:22 AM EDT
Terminated Phase 1 Interventional

Safety Study of MGD009 in B7-H3-expressing Tumors

NCT02628535
View directory record Official record
Conditions
Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non Small Cell Lung Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Thyroid Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Colon Cancer, Soft Tissue Sarcoma
Interventions
MGD009
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 25, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer

NCT01940276
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate, Prednisone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
14
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Detroit, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 25, 2026, 5:22 AM EDT
Completed Not applicable Interventional

MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer

NCT05127850
View directory record Official record
Conditions
Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
Consultation audio recording app
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 25, 2026, 5:22 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

NCT06216249
View directory record Official record
Conditions
Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, PSMA PET Scan, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 25, 2026, 5:22 AM EDT
Active, not recruiting Phase 2 Interventional

Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04754191
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Enfortumab vedotin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 25, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00036790
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, motexafin gadolinium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 25, 2026, 5:22 AM EDT
Completed No phase listed Observational

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability

NCT02663193
View directory record Official record
Conditions
Prostate Cancer
Interventions
No Intervention
Other
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Homewood, Alabama • La Mesa, California • Wheat Ridge, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 25, 2026, 5:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

NCT06782555
View directory record Official record
Conditions
Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
Interventions
Evofosfamide, Zalifrelimab, Balstilimab
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Oct 25, 2026, 5:22 AM EDT
Completed No phase listed Observational

Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone

NCT00392938
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
antiandrogen therapy, docetaxel, C-11 acetate PET scan, F-18 FDG PET scan, Tc-99m bone scan, CT scan of the chest, abdomen and pelvis
Drug · Diagnostic Test
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 25, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer

NCT00629057
View directory record Official record
Conditions
Androgen-insensitive Prostate Cancer
Interventions
MVA-BN-PRO
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Homewood, Alabama • Washington D.C., District of Columbia • Lawrenceville, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 25, 2026, 5:22 AM EDT
Withdrawn Phase 2 Interventional

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer

NCT01734681
View directory record Official record
Conditions
Prostate Cancer.
Interventions
G-202
Drug
Lead sponsor
GenSpera, Inc.
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Oct 25, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer

NCT00284752
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abraxane
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Vallejo, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 25, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer

NCT01815515
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
18F-DCFBC
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 25, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY3022855 In Participants With Breast or Prostate Cancer

NCT02265536
View directory record Official record
Conditions
Neoplasms, Neoplasm Metastasis
Interventions
LY3022855
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 25, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

Phase 1 of EC1169 In Patients With Recurrent MCRPC

NCT02202447
View directory record Official record
Conditions
Prostate Cancer
Interventions
EC1169, EC0652
Drug · Other
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Scottsdale, Arizona • New Haven, Connecticut • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 25, 2026, 5:22 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

NCT05884398
View directory record Official record
Conditions
Metastatic Castrate-sensitive Prostate Cancer
Interventions
Apalutamide, Androgen-deprivation Therapy (ADT)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

NCT00887198
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate, Placebo, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
48
States / cities
Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 25, 2026, 5:22 AM EDT
Active, not recruiting Phase 2 Interventional

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

NCT04592237
View directory record Official record
Conditions
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
Interventions
Cabazitaxel, Carboplatin, Cetrelimab, Niraparib
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 5:22 AM EDT